Skip to content
OVERVIEW
Veracyte is a leading genomic diagnostics company that is fundamentally improving patient care by resolving diagnostic uncertainty with evidence that is trustworthy and actionable. The company’s products uniquely combine genomic technology, clinical science and machine learning to provide answers that give physicians and patients a clear path forward without risky, costly surgery that is often unnecessary.
Since its founding in 2008, Veracyte has commercialized three genomic tests, which are transforming the diagnosis of thyroid cancer, lung cancer and idiopathic pulmonary fibrosis and collectively target a $2 billion market opportunity. Veracyte is based in South San Francisco, California. Veracyte’s common stock is listed on The NASDAQ Global Market under the symbol VCYT.

OVERVIEW

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Veracyte to Host Conference Call and Webcast to Discuss First Quarter 2018 Financial Results on Tuesday, May 1, 2018
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Apr. 17, 2018-- Veracyte, Inc. (Nasdaq: VCYT) announced today that it will report its first quarter 2018 financial results after the close of market on Tuesday, May 1, 2018 . Following the announcement, Veracyte will host a conference call and webcast
View HTML
Toggle Summary Veracyte Announces Precision Medicine Collaboration With Loxo Oncology
Agreement Leverages Veracyte’s New Afirma Xpression Atlas Platform SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Apr. 11, 2018-- Veracyte, Inc. (Nasdaq: VCYT) today announced a research collaboration through which Loxo Oncology will access Veracyte’s new Afirma ® Xpression Atlas platform to
View HTML

Events

Date Event Details
Summary Toggle Sep 8, 2016 11:00 AM EDT
Veracyte Percepta Medicare Coverage Conference Call
Summary Toggle Nov 29, 2016 3:30 PM EST
Piper Jaffray 28th Annual Healthcare Conference

Presentations

Title Documents

Veracyte Corporate Presentation, February 2018